IBM wins accolades for new mathematical prediction models to help determine the best drug combinations for any given HIV genetic variant. IBM reports it has won a Computerworld Honors Program Laureate for its health care IT work.
IBM said June 2 it has won a
Computerworld Honors Program Laureate for its contributions to the EuResist Network
GEIE research project for AIDS treatment. Developed by IBM
researchers in Haifa, Israel,
the project's new technologies and mathematical models help choose the best
drug combinations for any given HIV genetic variant.
EuResist is the only freely available data-driven computational method that
predicts the success of a treatment regimen against any given HIV genotype. Using
analytic technologies as well as viral genotype information, it is also the
only system providing the global medical community with an estimate of activity
for combination therapy rather than for individual drugs.
Researchers behind the EU-funded EuResist project have developed new
mathematical prediction models that not only take into account the patient's
own history, but tap into the wealth of information that EuResist researchers
have amassed.
IBM says health care IT clients have contributed to its success in the area of Web portal software. Click here to read more.
"The EuResist team feels both humbled and privileged by the opportunity
to put good science and state-of-the-art technologies at the service of such an
important and meaningful cause," Yardena Peres, researcher at the IBM
Research Lab in Haifa, said in a statement.
The recent expansion of the EuResist database to include 370,000 viral load
measurements and information from more than 33,000 patients and 98,000
therapies makes it the world's biggest database centered on HIV resistance and clinical
response information. The system's predictions are nearly 76 percent accurate,
outperforming other commonly used HIV resistance prediction tools and also
outperforming human experts in the field.
Email
Print
